Trial Search Results

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Novartis Pharmaceuticals

Stanford Investigator(s):


  • Drug: pasireotide LAR


Phase 2


Inclusion Criteria:

   - Male and Female Patients at least 18 years old

   - Patient who have rare tumors of neuroendocrine origin, such as tumors of the:

      1. pancreas

      2. pituitary glands

      3. Nelson syndrome

      4. ectopic-ACTH secreting tumor

   - Patients who have failed standard of care treatment or for whom no standard of care
   treatment exist

   - Signed Informed Consent

Exclusion Criteria:

   - Patients with active gallbladder disease

   - Patients with any ongoing or planned anti-neoplastic or interferon therapy

   - Poorly controlled diabetes mellitus

   - Female patients who are pregnant or lactating, or are of childbearing potential and
   not practicing a medically acceptable method of birth control

Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting